Figure 4.
Effects of IQ on TF antigen, activity, and gene expression. (A) Mean change from the baseline in the number of TF+ MVs showing reduction in both IQ and placebo groups but a significantly greater reduction in the placebo group (∗P = .02). (B) Mean change from the baseline in TF+ MV procoagulant activity (PCA), which is decreased in both groups but shows no significant difference (P = .51). (C) LPS-induced TF mRNA expression in PBMCs isolated from patients with SCD in the IQ group at baseline (BL) and after treatment (PT) showed a significant reduction in inducible TF mRNA after IQ treatment (∗∗P = .003; n = 20).